The University of Southampton
University of Southampton Institutional Repository

Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors

Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors
Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors

Lymphocyte transfusion from the marrow donor (DLT) is well established as an effective therapy for relapse of CML post allogeneic BMT. Reports thus far have been mostly limited to patients who received DLT from a matched sibling donor. We compared the efficacy and toxicity of DLT in 30 patients who were treated with cells from their HLA-identical sibling (n = 18) or from their phenotypically HLA-matched unrelated marrow donor (n = 12). The overall probability of obtaining a cytogenetic remission was 69% (95%CI: 51-83%) and was not significantly different between the two groups. The disease stage at the time of DLT was the only factor associated with cytogenetic remission by multivariate analysis; patients treated in cytogenetic or molecular relapse (n = 11) were seven times more likely (RR = 7.4, 95%CI: 2.4-22.4, P = 0.0005) to respond compared to patients treated for hematologic relapse (n = 19). There was a trend towards more acute GVHD II-IV in the unrelated donor group (58 vs 39%, P = 0.09), but the probability of developing extensive chronic GVHD was not significantly different (56 vs 39%, P = 0.4). We conclude that transfusion of donor cells from HLA-matched volunteer donors does not appreciably increase the risk of GVHD compared with transfusion of cells from HLA-identical siblings in patients with CML who relapse following allogeneic BMT. Conversely, there is no evidence for an increased graft-versus-leukemia effect after DLT from volunteer donors.

Adult, Bone Marrow Transplantation, Female, Graft vs Host Disease, Humans, Immunotherapy, Adoptive, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Lymphocyte Transfusion, Male, Middle Aged, Transplantation, Homologous, Journal Article, Research Support, Non-U.S. Gov't
0268-3369
1055-61
van Rhee, F
0928f5f5-f11e-4e3f-a3e4-8e27910398eb
Savage, D
6528dac6-630a-4af4-9ccd-4f1e9c18b76c
Blackwell, J
70e64d88-90fc-4500-ad9c-952cdeee4a07
Orchard, K
794654ab-d6cc-488a-ac11-c9217433c7a2
Dazzi, F
7ef9de2e-64dc-4712-8a96-f37b551751ed
Lin, F
9067ee54-a57f-4432-b390-ec81fd8aa73c
Chase, A
a40a09c2-3073-4655-ba0b-a802e34914b5
Bungey, J
6843e16a-9534-4690-a896-287f9d8094ec
Cross, N C
f87650da-b908-4a34-b31b-d62c5f186fe4
Apperley, J
622c945c-74c1-4773-a80f-2bdafe8dfe14
Szydlo, R
0d3b4cfd-5301-4a6b-8478-3f7ccef56bef
Goldman, J M
2c27a1b3-c445-4593-a6b5-2e6e749fa1cb
van Rhee, F
0928f5f5-f11e-4e3f-a3e4-8e27910398eb
Savage, D
6528dac6-630a-4af4-9ccd-4f1e9c18b76c
Blackwell, J
70e64d88-90fc-4500-ad9c-952cdeee4a07
Orchard, K
794654ab-d6cc-488a-ac11-c9217433c7a2
Dazzi, F
7ef9de2e-64dc-4712-8a96-f37b551751ed
Lin, F
9067ee54-a57f-4432-b390-ec81fd8aa73c
Chase, A
a40a09c2-3073-4655-ba0b-a802e34914b5
Bungey, J
6843e16a-9534-4690-a896-287f9d8094ec
Cross, N C
f87650da-b908-4a34-b31b-d62c5f186fe4
Apperley, J
622c945c-74c1-4773-a80f-2bdafe8dfe14
Szydlo, R
0d3b4cfd-5301-4a6b-8478-3f7ccef56bef
Goldman, J M
2c27a1b3-c445-4593-a6b5-2e6e749fa1cb

van Rhee, F, Savage, D, Blackwell, J, Orchard, K, Dazzi, F, Lin, F, Chase, A, Bungey, J, Cross, N C, Apperley, J, Szydlo, R and Goldman, J M (1998) Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplantation, 21 (10), 1055-61. (doi:10.1038/sj.bmt.1701224).

Record type: Article

Abstract

Lymphocyte transfusion from the marrow donor (DLT) is well established as an effective therapy for relapse of CML post allogeneic BMT. Reports thus far have been mostly limited to patients who received DLT from a matched sibling donor. We compared the efficacy and toxicity of DLT in 30 patients who were treated with cells from their HLA-identical sibling (n = 18) or from their phenotypically HLA-matched unrelated marrow donor (n = 12). The overall probability of obtaining a cytogenetic remission was 69% (95%CI: 51-83%) and was not significantly different between the two groups. The disease stage at the time of DLT was the only factor associated with cytogenetic remission by multivariate analysis; patients treated in cytogenetic or molecular relapse (n = 11) were seven times more likely (RR = 7.4, 95%CI: 2.4-22.4, P = 0.0005) to respond compared to patients treated for hematologic relapse (n = 19). There was a trend towards more acute GVHD II-IV in the unrelated donor group (58 vs 39%, P = 0.09), but the probability of developing extensive chronic GVHD was not significantly different (56 vs 39%, P = 0.4). We conclude that transfusion of donor cells from HLA-matched volunteer donors does not appreciably increase the risk of GVHD compared with transfusion of cells from HLA-identical siblings in patients with CML who relapse following allogeneic BMT. Conversely, there is no evidence for an increased graft-versus-leukemia effect after DLT from volunteer donors.

This record has no associated files available for download.

More information

Published date: May 1998
Keywords: Adult, Bone Marrow Transplantation, Female, Graft vs Host Disease, Humans, Immunotherapy, Adoptive, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Lymphocyte Transfusion, Male, Middle Aged, Transplantation, Homologous, Journal Article, Research Support, Non-U.S. Gov't
Organisations: Cancer Sciences, Human Development & Health

Identifiers

Local EPrints ID: 411601
URI: http://eprints.soton.ac.uk/id/eprint/411601
ISSN: 0268-3369
PURE UUID: 6847c599-b939-431a-a5c5-2d5df650e163
ORCID for K Orchard: ORCID iD orcid.org/0000-0003-2276-3925
ORCID for A Chase: ORCID iD orcid.org/0000-0001-6617-9953
ORCID for N C Cross: ORCID iD orcid.org/0000-0001-5481-2555

Catalogue record

Date deposited: 21 Jun 2017 16:31
Last modified: 16 Mar 2024 03:26

Export record

Altmetrics

Contributors

Author: F van Rhee
Author: D Savage
Author: J Blackwell
Author: K Orchard ORCID iD
Author: F Dazzi
Author: F Lin
Author: A Chase ORCID iD
Author: J Bungey
Author: N C Cross ORCID iD
Author: J Apperley
Author: R Szydlo
Author: J M Goldman

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×